Results 161 to 170 of about 94,075 (262)
British Journal of Pharmacology, EarlyView.Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller +3 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Ketamine consists of two enantiomers, (R)‐ketamine and (S)‐ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)‐enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)‐ketamine.
Szabolcs Koncz +4 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Maternal hypoxia is a recognised risk factor for neurodevelopmental disorders in offspring. Although rodent models of hypoxia have been reported, the detailed pathogenesis of maternal hypoxia‐induced neurodevelopmental disorders remains unclear.
Kentaro Tokudome +6 more
wiley +1 more source
Cell Proliferation, EarlyView.Clinical‐grade HLA‐homozygous iPSC‐derived neural precursor cells restore motor function, rebuild striatal circuitry and reduce neuroinflammation in QA‐lesioned rats. These findings demonstrate robust neuronal replacement and microenvironment modulation, supporting their potential as a regenerative therapy for Huntington's disease.
Hyeonjoong Jeon +6 more
wiley +1 more source
Human IDO2 exhibits unique binding affinities distinct to those of human IDO1
The FEBS Journal, EarlyView.Although indoleamine 2,3‐dioxygenase 2 (IDO2) is highly homologous to IDO1, it displays markedly lower catalytic activity. We found that IDO2 binds L‐tryptophan (L‐Trp) in a flipped orientation stabilized by the IDO2‐specific residue His143. Replacement of His143 with the IDO1‐equivalent tyrosine restored an IDO1‐like binding mode and increased ...
Shunsuke Nogi +8 more
wiley +1 more source
Glioblastoma mimicking anti‐NMDA receptor encephalitis: a case series
Internal Medicine Journal, EarlyView.Abstract Anti‐N‐methyl‐D‐aspartate receptor (anti‐NMDAR) GluN1‐IgG antibodies are the hallmark of anti‐NMDAR encephalitis, a common type of autoimmune encephalitis. We describe two men with seizures and asymmetric, mass‐like temporal lesions initially treated as anti‐NMDAR encephalitis: Case 1 had serum and cerebrospinal fluid (CSF) NMDAR‐IgG ...
Sophie Chatterton +7 more
wiley +1 more source